N. L. Berinstein

416 total citations
18 papers, 321 citations indexed

About

N. L. Berinstein is a scholar working on Pathology and Forensic Medicine, Oncology and Genetics. According to data from OpenAlex, N. L. Berinstein has authored 18 papers receiving a total of 321 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Pathology and Forensic Medicine, 8 papers in Oncology and 5 papers in Genetics. Recurrent topics in N. L. Berinstein's work include Lymphoma Diagnosis and Treatment (12 papers), Chronic Lymphocytic Leukemia Research (5 papers) and Monoclonal and Polyclonal Antibodies Research (5 papers). N. L. Berinstein is often cited by papers focused on Lymphoma Diagnosis and Treatment (12 papers), Chronic Lymphocytic Leukemia Research (5 papers) and Monoclonal and Polyclonal Antibodies Research (5 papers). N. L. Berinstein collaborates with scholars based in Canada, Brazil and United States. N. L. Berinstein's co-authors include Marciano D. Reis, Carol Sawka, E. Franssen, Shou Ching Tang, Jean B. Robinson, David Spaner, Kevin Imrie, Rena Buckstein, Larissa Derzko-Dzulynsky and P. H. Pinkerton and has published in prestigious journals such as Journal of Clinical Oncology, Blood and The Journal of Immunology.

In The Last Decade

N. L. Berinstein

18 papers receiving 317 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
N. L. Berinstein Canada 11 197 128 120 86 82 18 321
Olivia Minelli Italy 10 197 1.0× 121 0.9× 102 0.8× 36 0.4× 99 1.2× 12 325
H Stein Germany 7 222 1.1× 136 1.1× 105 0.9× 68 0.8× 137 1.7× 15 380
J. J. Sotto France 6 154 0.8× 131 1.0× 119 1.0× 165 1.9× 155 1.9× 13 382
Steve Shuey United States 5 250 1.3× 144 1.1× 156 1.3× 179 2.1× 153 1.9× 5 430
BM Wilkes United States 6 244 1.2× 125 1.0× 186 1.6× 44 0.5× 203 2.5× 8 410
Eileen Sussman United States 6 280 1.4× 149 1.2× 125 1.0× 67 0.8× 181 2.2× 9 402
Noboru Yonetani Japan 9 292 1.5× 192 1.5× 174 1.4× 25 0.3× 69 0.8× 21 388
JG Gribben United States 5 285 1.4× 225 1.8× 161 1.3× 40 0.5× 85 1.0× 6 430
I Bolz Germany 11 331 1.7× 196 1.5× 192 1.6× 47 0.5× 148 1.8× 17 562
RJ Lukes United States 8 282 1.4× 128 1.0× 239 2.0× 30 0.3× 151 1.8× 10 436

Countries citing papers authored by N. L. Berinstein

Since Specialization
Citations

This map shows the geographic impact of N. L. Berinstein's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by N. L. Berinstein with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites N. L. Berinstein more than expected).

Fields of papers citing papers by N. L. Berinstein

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by N. L. Berinstein. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by N. L. Berinstein. The network helps show where N. L. Berinstein may publish in the future.

Co-authorship network of co-authors of N. L. Berinstein

This figure shows the co-authorship network connecting the top 25 collaborators of N. L. Berinstein. A scholar is included among the top collaborators of N. L. Berinstein based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with N. L. Berinstein. N. L. Berinstein is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
2.
Berinstein, N. L., Michael A. Morse, Howard L. Kaufman, et al.. (2011). A phase I study of the safety and immunogenicity of a therapeutic vaccine, DPX-0907 in patients with advanced-stage ovarian, breast, or prostate cancer.. Journal of Clinical Oncology. 29(15_suppl). e13050–e13050. 4 indexed citations
3.
Berinstein, N. L., Rena Buckstein, Kevin Imrie, et al.. (2002). Bcl-2 clearance: optimising outcomes in follicular non-Hodgkin's lymphoma. Bone Marrow Transplantation. 29(S1). S14–S17. 13 indexed citations
4.
MacKenzie, Robert G., E. Franssen, Rebecca Wong, et al.. (2000). Risk-Adapted Therapy for Clinical Stage I–II Hodgkin's Disease: 7-Year Results of Radiotherapy Alone for Low-Risk Disease, and ABVD and Radiotherapy for High-Risk Disease. Clinical Oncology. 12(5). 278–288. 4 indexed citations
5.
Buckstein, Rena, Kevin Imrie, David Spaner, et al.. (2000). In Vivo Purging With Rituximab Prior to Stem Cell Collection Is Associated With Persistent Molecular Evidence of t(14;18) That Often Disappears Post-Transplant in Patients With Follicular Lymphoma. 1 indexed citations
6.
Sawka, Carol, et al.. (1999). Delivery of Full Dose CHOP Chemotherapy to Elderly Patients with Aggressive Non-Hodgkin's Lymphoma without G-CSF Support. Leukemia & lymphoma. 35(1-2). 119–127. 15 indexed citations
7.
Buckstein, Rena, Kevin Imrie, David Spaner, et al.. (1999). Stem cell function and engraftment is not affected by "in vivo purging" with rituximab for autologous stem cell treatment for patients with low-grade non-Hodgkin's lymphoma.. PubMed. 26(5 Suppl 14). 115–22. 61 indexed citations
8.
Derzko-Dzulynsky, Larissa, Alan R. Berger, & N. L. Berinstein. (1998). Cytomegalovirus retinitis and low-grade non-Hodgkin's lymphoma: Case report and review of the literature. American Journal of Hematology. 57(3). 228–232. 15 indexed citations
9.
Tang, Shou Ching, et al.. (1996). Immunosuppressive Toxicity of CAMPATH®1H Monoclonal Antibody in the Treatment of Patients with Recurrent Low Grade Lymphoma. Leukemia & lymphoma. 24(1-2). 93–101. 45 indexed citations
10.
Verkoczy, Laurent, et al.. (1995). Rearrangement and expression of the human psi C lambda 6 gene segment results in a surface Ig receptor with a truncated light chain constant region.. The Journal of Immunology. 154(9). 4583–4591. 4 indexed citations
11.
Berinstein, N. L., et al.. (1995). A mutated promoter of a human Ig V lambda gene segment is associated with reduced germ-line transcription and a low frequency of rearrangement.. The Journal of Immunology. 154(4). 1748–1761. 30 indexed citations
12.
13.
Berinstein, N. L., et al.. (1994). Identification of a new human V lambda gene family--V lambda X.. The Journal of Immunology. 152(10). 4969–4975. 19 indexed citations
14.
15.
16.
Daley, M. Denise, N. L. Berinstein, & Kathy Siminovitch. (1994). Immunoglobulin heavy chain variable gene utilization in human large cell and Burkitt's lymphoma cell lines.. PubMed. 17(6). 522–30. 6 indexed citations
17.
Berinstein, N. L., et al.. (1992). Absence of immunoglobulin variable region hypermutation in a large cell lymphoma after in vivo and in vitro propagation. Blood. 80(3). 738–743. 14 indexed citations
18.
Berinstein, N. L., et al.. (1992). Absence of immunoglobulin variable region hypermutation in a large cell lymphoma after in vivo and in vitro propagation. Blood. 80(3). 738–743. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Olivia Minelli Breakdown of academic impact, for papers by H Stein Breakdown of academic impact, for papers by J. J. Sotto Breakdown of academic impact, for papers by Steve Shuey Breakdown of academic impact, for papers by BM Wilkes Breakdown of academic impact, for papers by Eileen Sussman Breakdown of academic impact, for papers by Noboru Yonetani Breakdown of academic impact, for papers by JG Gribben Breakdown of academic impact, for papers by I Bolz Breakdown of academic impact, for papers by RJ Lukes
Rankless by CCL
2026